Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLOHA-2: TSC-101 in AML and MDS Post-Transplant
NCT07702578Phase 3Active, not recruiting
- Sponsor
- TScan Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 3, open-label trial of TSC-101 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by TScan Therapeutics. Primary endpoint: Relapse-free survival at 3 years. Started Jun 2026; status: active, not recruiting.
02
Drugs
TSC-101
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07702578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702578.